The Nlrp3 inflammasome admits defeat

Trends Immunol. 2015 Jun;36(6):323-4. doi: 10.1016/j.it.2015.05.001. Epub 2015 May 16.

Abstract

The Nlrp3 inflammasome triggers interleukin-1 secretion by myeloid cells in response to endogenous and exogenous danger signals. Two recent studies identified the sulfonylurea MCC950 and the ketone metabolite β-hydroxybutyrate as specific inhibitors of the Nlrp3 inflammasome, with promising therapeutic potential for the treatment of auto-inflammatory diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • 3-Hydroxybutyric Acid / pharmacology*
  • Animals
  • Carrier Proteins / antagonists & inhibitors*
  • Caspase 1 / drug effects*
  • Cryopyrin-Associated Periodic Syndromes / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Female
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Inflammasomes / antagonists & inhibitors*
  • Interleukin-1beta / drug effects*
  • Male
  • Monocytes / drug effects*
  • Multiple Sclerosis*
  • Sulfones / therapeutic use*

Substances

  • Carrier Proteins
  • Heterocyclic Compounds, 4 or More Rings
  • Inflammasomes
  • Interleukin-1beta
  • Sulfones
  • Caspase 1
  • 3-Hydroxybutyric Acid